CXC chemokines located in the 4q21 region are up-regulated in breast cancer

Endocrine-Related Cancer

Volumn 14, Issue 4, 2007, Pages 1039-1052

  Bièche, Ivan ^c   Chavey, Carine ^a,b   Andrieu, Catherine ^c   Busson, Muriel ^a,b   Vacher, Sophie ^c   Le Corre, Ludovic ^a,b   Guinebretière, Jean Marc ^c   Burlinchon, Sandrine ^a,b   Lidereau, Rosette ^c   Lazennec, Gwendal ^a,b,d  

^a UMR 9004 Centre national de la recherche scientifique   (France)

^b UNIV MONTPELLIER   (France)

^c CENTRE RENÉ HUGUENIN   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL4 CHEMOKINE; CXCL7 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ESTROGEN RECEPTOR ALPHA; GRANULOCYTE CHEMOTACTIC PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; TAMOXIFEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD CELL; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME 4Q; CLINICAL ARTICLE; CLUSTER ANALYSIS; EPITHELIUM CELL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; METASTASIS; NUCLEOTIDE SEQUENCE; QUANTITATIVE ANALYSIS; RELAPSE; TUMOR BIOPSY; TUMOR CELL; UPREGULATION;

EID: 36148979810     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01301     Document Type: Article

References (45)

1. Addison CL, Daniel TO, Burdick MD, Liu H, Ehlert JE, Xue YY, Buechi L, Walz A, Richmond A & Strieter RM 2000 The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. Journal of Immunology 165 5269-5277.
2. Balkwill F 2004 Cancer and the chemokine network. Nature Reviews. Cancer 4 540-550.
3. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, Nicholas RW & Suva LJ 2002 Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Research 62 5571-5579.
4. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB & Dirix LY 2002 Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clinical Breast Cancer 2 311-315.
5. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB & Dirix LY 2004 Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clinical Cancer Research 10 7157-7162.
6. Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R & Vidaud M 1999 Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clinical Chemistry 45 1148-1156.
7. Bieche I, Parfait B, Le Doussal V, Olivi M, Rio M-C, Lidereau R & Vidaud M 2001 Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Research 61 1652-1658.
8. Bloom HJ & Richardson WW 1957 Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. British Journal of Cancer 11 359-377.
9. Clark-Lewis I, Dewald B, Geiser T, Moser B & Baggiolini M 1993 Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. PNAS 90 3574-3577.
10. Didier G, Brezellec P, Remy E & Henaut A 2002 GeneANOVA - gene expression analysis of variance. Bioinformatics 18 490-491.
11. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F & Lazennec G 2003 IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22 256-265.
12. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, Vignon F & Lazennec G 2004 Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23 6105-6114.
13. Green AR, Green VL, White MC & Speirs V 1997 Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. International Journal of Cancer 72 937-941.
14. Hanley JA & McNeil BJ 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 29-36.
15. Hebert CA, Vitangcol RV & Baker JB 1991 Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. Journal of Biological Chemistry 266 18989-18994.
16. Jiang XP, Yang DC, Elliott RL & Head JF 2000 Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. Cytokine 12 458-465.
17. Kaplan E & Meier P 1958 Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53 457-481.
18. Kozlowski L, Zakrzewska I, Tokajuk P & Wojtukiewicz MZ 2003 Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Roczniki Akademii Medycznej w Bialymstoku 48 82-84.
19. De Larco JE, Wuertz BR, Manivel JC & Furcht LT 2001 Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Research 61 2857-2861.
20. Lazennec G, Bresson D, Lucas A, Chauveau C & Vignon F 2001 ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142 4120-4130.
21. Li A, Varney ML & Singh RK 2004 Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype. Clinical and Experimental Metastasis 21 571-579.
22. Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C & Huang RP 2004 Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. International Journal of Cancer 109 507-515.
23. Loukinova E, Dong G, Enamorado-Ayalya I, Thomas GR, Chen Z, Schreiber H & Van Waes C 2000 Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19 3477-3486.
24. Luster AD 1998 Chemokines-chemotactic cytokines that mediate inflammation. New England Journal of Medicine 338 436-445.
25. Mann H & Whitney D 1947 On a test of whether one of two random variables is stochastically larger than the other. Annals of Mathematical Statistics 18 50-60.
26. Mantovani A 1999 The chemokine system: redundancy for robust outputs. Immunology Today 20 254-257.
27. Moser B, Wolf M, Walz A & Loetscher P 2004 Chemokines: multiple levels of leukocyte migration control. Trends in Immunology 25 75-84.
28. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN et al. 2001 Involvement of chemokine receptors in breast cancer metastasis. Nature 410 50-56.
29. Osborne CK 1998 Steroid hormone receptors in breast cancer management. Breast Cancer Research and Treatment 51 227-238.
30. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE, Duska LR, Fuller AF, Goodman AK, Nikrui N et al. 2000 Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. International Journal of Gynecological Cancer 10 33-41.
31. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J & Smith PG 1977 Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. British Journal of Cancer 35 1-39.
32. Proudfoot AE 2002 Chemokine receptors: multifaceted therapeutic targets. Nature Reviews. Immunology 2 106-115.
33. Rossi D & Zlotnik A 2000 The biology of chemokines and their receptors. Annual Review of Immunology 18 217-242.
34. Salcedo R, Resau JH, Halverson D, Hudson EA, Dambach M, Powell D, Wasserman K & Oppenheim JJ 2000 Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB Journal 14 2055-2064.
35. Sheikh MS, Garcia M, Pujol P, Fontana JA & Rochefort H 1994 Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers? Invasion and Metastasis 14 329-336.
36. Skoog L, Humla S, Axelsson M, Frost M, Norman A, Nordenskjold B & Wallgren A 1987 Estrogen receptor levels and survival of breast cancer patients. A study on patients participating in randomized trials of adjuvant therapy. Acta Oncologica 26 95-100.
37. Smadja DM, Bieche I, Uzan G, Bompais H, Muller L, Boisson-Vidal C, Vidaud M, Aiach M & Gaussem P 2005 PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis in vitro with upregulation of the SDF-1/CXCR4 system. Arteriosclerosis, Thrombosis, and Vascular Biology 25 2321-2327.
38. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, Desai SB & Atkin SL 1998 Short-term primary culture of epithelial cells derived from human breast tumours. British Journal of Cancer 78 1421-1429.
39. Strieter RM, Polverini PJ, Arenberg DA & Kunkel SL 1995 The role of CXC chemokines as regulators of angiogenesis. Shock 4 155-160.
40. Strieter RM, Burdick MD, Gomperts BN, Belperio JA & Keane MP 2005 CXC chemokines in angiogenesis. Cytokine and Growth Factor Reviews 16 593-609.
41. Walser TC & Fulton AM 2004 The role of chemokines in the biology and therapy of breast cancer. Breast Disease 20 137-143.
42. Wood LD & Richmond A 1995 Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GRO alpha gene requires both NF-κB and novel constitutive factors. Journal of Biological Chemistry 270 30619-30626.
43. Yang J & Richmond A 2001 Constitutive IkappaB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Research 61 4901-4909.
44. Youngs SJ, Ali SA, Taub DD & Rees RC 1997 Chemokines induce migrational responses in human breast carcinoma cell lines. International Journal of Cancer 71 257-266.
45. Zhu YM & Woll PJ 2005 Mitogenic effects of interleukin-8/CXCL8 on cancer cells. Future Oncology 1 699-704.